Related Experiment Video
Updated: Dec 13, 2025

An Integrated Platform for Genome-wide Mapping of Chromatin States Using High-throughput ChIP-sequencing in Tumor Tissues
Published on: April 5, 2018
NuRD subunit CHD4 regulates super-enhancer accessibility in rhabdomyosarcoma and represents a general tumor
Joana G Marques1, Berkley E Gryder2, Blaz Pavlovic1
1Department of Oncology and Children's Research Center, University Children's Hospital, Zurich, Switzerland.
Abstract:
The NuRD complex subunit CHD4 is essential for fusion-positive rhabdomyosarcoma (FP-RMS) survival, but the mechanisms underlying this dependency are not understood. Here, a NuRD-specific CRISPR screen demonstrates that FP-RMS is particularly sensitive to CHD4 amongst the NuRD members. Mechanistically, NuRD complex containing CHD4 localizes to super-enhancers where CHD4 generates a chromatin architecture permissive for the binding of the tumor driver and fusion protein PAX3-FOXO1, allowing downstream transcription of its oncogenic program. Moreover, CHD4 depletion removes HDAC2 from the chromatin, leading to an increase and spread of histone acetylation, and prevents the positioning of RNA Polymerase 2 at promoters impeding transcription initiation. Strikingly, analysis of genome-wide cancer dependency databases identifies CHD4 as a general cancer vulnerability. Our findings describe CHD4, a classically defined repressor, as positive regulator of transcription and super-enhancer accessibility as well as establish this remodeler as an unexpected broad tumor susceptibility and promising drug target for cancer therapy.
Insights
Chromatin remodeler CHD4 is crucial for fusion-positive rhabdomyosarcoma (FP-RMS) by regulating super-enhancers. This study reveals CHD4 as a broad cancer vulnerability and potential therapeutic target.
Area of Science:
- Molecular Biology
- Cancer Biology
- Epigenetics
Background:
- The NuRD complex subunit CHD4 is vital for fusion-positive rhabdomyosarcoma (FP-RMS) survival.
- The precise mechanisms of this dependency are not fully understood.
Purpose of the Study:
- To elucidate the role of CHD4 in FP-RMS pathogenesis.
- To identify CHD4 as a potential therapeutic target in cancer.
Main Methods:
- Utilized a NuRD-specific CRISPR screen to assess sensitivity to NuRD members in FP-RMS.
- Investigated the localization of CHD4 to super-enhancers and its effect on transcription factor binding.
- Analyzed genome-wide cancer dependency databases to identify general cancer vulnerabilities.
Main Results:
- FP-RMS exhibits particular sensitivity to CHD4 depletion among NuRD members.
- CHD4 facilitates PAX3-FOXO1 binding to super-enhancers, enabling oncogenic transcription.
- CHD4 depletion disrupts histone acetylation patterns and impedes RNA Polymerase II initiation.
- CHD4 is identified as a general cancer vulnerability across various cancer types.
Conclusions:
- CHD4 acts as a positive regulator of transcription and super-enhancer accessibility, contrary to its classical role as a repressor.
- CHD4 is an unexpected, broad tumor susceptibility factor and a promising therapeutic target for cancer treatment.
Related Concept Videos
Abnormal Proliferation
Hedgehog Signaling Pathway
The Ras Gene
Ras is a...
Cadherins in Tissue Organization
Cell Sorting During Development
Cell sorting plays an...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Master Transcription Regulators

